@article{article, title  = {{Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA)  RADAR trial in newly diagnosed transplant eligible patients}},

 publisher = {{American Society of Hematology}},

 url = {{https://doi.org/10.1182/blood-2025-98 }},

 year = {{2025}},

 month = {{11}},

 author = {{Ramasamy K and Royle K-L and Cicero R and de Tute R and Jenner M and Bygrave C and Popat R and Mehta D and Chiecchio L and Balik B and Kazeroun M et al}},

 doi = {{10.1182/blood-2025-98}},

 volume = {{146}},

 journal = {{Blood}},

 issue = {{Supplement 1}},

 pages = {{98-98}},

 note = {{Accessed on 2026/07/16}}}